Previous Next

New ImmunoAtlas Reports

Simultaneous PD-L1 testing in cancers using mIHC/IF

from Joe Yeong's Lab, 29th Nov 2020

A study based on simultaneous detection and quantification of three different programmed death-ligand 1 (PD-L1) antibodies found moderate-to-strong correlations between their staining levels in conventional immunohistochemistry (IHC) and multiplex immunohistochemistry/ immunofluorescence (mIHC/IF).

first story thumbnail a
Simultaneous staining of EpCAM antibody (red) and three PD-L1 antibodies: 22C3 (magenta), SP142 (yellow) and SP263 (green) in cancer tissues.

CD38, a possible predictive marker of immunotherapy responsiveness in hepatocellular carcinoma

from Joe Yeong's Lab, 26th Nov 2020

A study showed that quantifications of CD38+ cells and CD38+CD68+ macrophages can more accurately predict immune-checkpoint-blockade responsiveness than quantifications based on programmed death-ligand 1 (PD-L1) or CD8+ T cells only.

second story thumbnail b
HCC tissues stained with CD38 (yellow), PD-L1 (green), macrophage marker CD68 (red) and cell nuclei (blue).

Whole-slide IHC and mIHC/IF imaging of the same tissue section

from Joe Yeong's Lab, 7th Dec 2020

A new study performed whole-slide multiplexed immunohistochemistry and immunofluorescence (mIHC/IF) and hematoxylin and eosin (H&E) staining and imaging on the same human tonsil section. This is a promising method to simultaneously and spatially quantify overall tissue morphology and various molecular phenotypes of cancer and immune cells in the tumor microenvironments.

mIHC/IF thumbnail
H&E thumbnail
Whole slide mIHC/IF image (left) of human tonsil tissue stained with DNA (blue), CD20 (cyan), CD45 (green), CD3 (magenta) and CD68 (orange), and its corresponding H&E staining (right).